Financial intelligence for Asia's healthcare markets
Remember me:

Analysis: The opportunities of diabetes in Asia

“The Asia-Pacific region presents lucrative opportunities for multinational pharmaceutical firms that treat diabetes,” says BMI Research in Singapore in a new report on healthcare in Asia. Fuelled by rapid urbanisation, nutrition transition and increasingly sedentary lifestyles, the epidemic has grown in parallel with the worldwide rise in obesity. Asia’s large population and rapid economic development have made it an epicentre of the epidemic, with India and China the key hotspots in the region, it explains.

The World Health Organisation (WHO) reckons that 80% of diabetes deaths occur in low- and middle-income countries, and forecasts that these deaths will double between 2016 and 2030. The epidemic of diabetes, as well as the burden of related non-communicable diseases, is challenging public health and hospital systems around the world – particularly in the Asia-Pacific region. Though the prevalence of obesity in Asia is relatively low compared with that across Western populations, BMI argues that Asia Pacific’s vast population and rapid economic development presents significant opportunities for companies in diabetes therapeutic field.

The size of the problem is significant. Patients with diabetes in Asia now account for more than 60% of the global diabetic population, with the majority residing in the largest and most populous countries; India and China.

 “We note that India and China are by far the two largest markets in the region for diabetes medicines,” writes BMI. According to International Diabetes Federation, there were 69.1 million cases of diabetes in India in 2015 and 109 million cases of diabetes in China. Last year, India’s population lost 9.2 million disability-adjusted life years to diabetes, China lost 8.2 million years and Indonesia lost 2.9 million years. “The significant increase in the prevalence of diabetes in India and China has occurred over a short period of time, largely driven by sedentary lifestyles and unhealthy diets,” it adds.

Due to elevated behavioural risks causing a strain on the region’s healthcare systems, governments have begun to introduce initiatives aimed at reversing this trend. Moreover, given the high financial burden of treating diabetes, there will be greater emphasis placed on preventative care. In India, BMI cites a national programme for control of diabetes has been rolled out across the country, to improve diabetes awareness levels at a national level. The government has also imposed a hefty tax of 28% on diabetes-inducing food substances under the Goods and Services Tax regime in an attempt to dissuade consumption of unhealthy food. And in China, World Diabetes Day and several similarly themed publicity events have been used to spread information on diabetes prevention and to raise public health literacy. Public health lifestyle campaigns have been pushed forward to advocate rational diet and adequate exercise, and to discourage smoking and the consumption of alcohol.

Posted on: 14/06/2017 UTC+08:00


Shares in Sisram Medical, a Israeli subsidiary of Shanghai Fosun Pharmaceutical, and which manufactures medical aesthetics devices, slumped on their Hong Kong Stock Exchange debut today. By late morning they were down more than 6%.
Auckland-based ehealth software company Orion Health has signed a five-year contract with Integrated Health Information Systems (IHiS), the health technology agency for Singapore.
Irish healthcare, IT and services company Clanwilliam Group has taken a majority shareholding in HealthLink, Australasia’s leading health-system integrator. Financial terms have not been disclosed.
Strategic initiatives and expansion have driven a rise in first quarter profits at iKang Healthcare Group, China’s largest private preventive healthcare services provider.
Optiscan Imaging, which develops microscopic imaging technologies for medical markets, has announced an exclusive distribution agreement with Chinese based China Gate Scientific for the newest Optiscan preclinical research system, ViewnVivo.
Contract genomics organisation WuXi NextCODE has appointed Rob Brainin as executive vice president and chief operating officer. Brainin joins the company from Illumina, where he was vice president and general manager of life sciences and applied genomics.
Melbourne-based medtech company Novita Healthcare has appointed Bruce Higgins as chairman. He is an experienced non- executive director, chairman and former chief executive of both private and listed companies within Australia and internationally, spanning over 25 years in diverse companies ranging from engineering, manufacturing and professional services to larger contracting businesses.
In what is another setback for Perth-based digital healthcare operator Resapp, Médecins Sans Frontières/Doctors Without Borders has decided not proceed with its planned field evaluation of the group’s software. ResApp’s main product is a cough-based diagnostic test that works with a smartphone to analyse the sound of a patient’s cough and to diagnose any underlying conditions.


By 2042 there will be more over-65s in Asia than the populations of the Eurozone and North America combined. We look at the business opportunities this creates.
Albert Wong argues that biomedical technology should not be ignored and explains how the Hong Kong Science and Technology Parks Corporation can support it.
Jacob Pope explains why medical tourism remains one of the region’s most significant industries.
APACMed’s Fredrik Nyberg looks at how local and multinational IVD companies are developing novel solutions for Asia’s unique needs.
It is perhaps a curious line in the sand to draw, but the new hospital in Dunedin, the second-largest city in the South Island of New Zealand, is gearing up to be a significant battle in the use of private-public partnership funding in the APAC region.
The ADB’s Eduardo Banzon argues that ASEAN countries need to guarantee the same health coverage for citizens when they are in foreign countries.
Mercer’s Catherine Li explains how companies in China can avoid common pitfalls when they establish employee health management programmes.
Lieven Jacquemyn, PPP international development director at GE Healthcare Singapore, discusses how governments, providers and investors can work together to bring universal health coverage to the region.


HealthInvestor Asia Summit



Hedge Fund Focus

HealthInvestor Asia twitter feed
HIA Indices